Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2852-2856

  Wenning, Larissa A ^a   Hanley, William D ^a   Brainard, Diana M ^a   Petry, Amelia S ^a   Ghosh, Kalyan ^a   Jin, Bo ^a   Mangin, Eric ^a   Marbury, Thomas C ^b   Berg, Jolene K ^c   Chodakewitz, Jeffrey A ^a   Stone, Julie A ^a   Gottesdiener, Keith M ^a   Wagner, John A ^a   Iwamoto, Marian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c CEDRA Clinical Research LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; INTEGRASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INHIBITION; FEMALE; FLATULENCE; GLUCURONIDATION; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINE COLOR;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RIFAMPIN; YOUNG ADULT;

EID: 66949149605     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01468-08     Document Type: Article

References (23)

1. Asante-Appiah, E., and A. M. Skalka. 1999. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 52:351-369.
2. Bachmann, K. A., and L. Jauregui. 1993. Use of single sample clearance estimates of cytochrome-P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 23:307-315.
3. Baciewicz, A. M., C. R. Chrisman, C. K. Finch, and T. H. Self. 2008. Update on rifampin and rifabutin drug interactions. Am. J. Med. Sci. 335:126-136.
4. Brainard, D. M., A. Petry, W. D. Hanley, L. A. Wenning, B. Jin, S. E. Breidinger, J. Berg, J. A. Stone, J. A. Wagner, and M. Iwamoto. 2008. Doubling the dose of raltegravir (RAL) does not increase trough levels in the presence of rifampin (RIF), abstr. A-964, p. 18. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. and Infect. Dis. Soc. Am. 46th Annu. Meet. (ICAAC/IDSA) (a joint meeting), Washington, DC, 2008.
5. Chung, J. Y., J. Y. Cho, K. S. Yu, J. R. Kim, H. R. Jung, K. S. Lim, I. J. Jang, and S. G. Shin. 2005. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin. Pharmacol. Ther. 77:486-494.
6. Cooper, D., J. Gatell, J. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin, X. Xu, R. Isaacs, H. Teppler, and B.-Y. Nguyen. 2008. 48-Week results from BENCHMRK-1, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1, abstr. J-114. 15th Conf. Retrovir. Opportun. Infect., Boston, MA, 3 to 6 February 2008.
7. Esposito, D., and R. Craigie. 1999. HIV integrase structure and function. Adv. Virus Res. 52:319-333.
8. Gallicano, K. D., J. Sahai, V. K. Shukla, I. Seguin, A. Pakuts, D. Kwok, B. C. Foster, and D. W. Cameron. 1999. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br. J. Clin. Pharmacol. 48:168-179.
9. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R. D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269.
10. Iwamoto, M., K. Kassahun, M. D. Troyer, W. D. Hanley, P. Lu, A. Rhoton, A. S. Petry, K. Ghosh, E. Mangin, E. P. DeNoia, L. A. Wenning, J. A. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J. Clin. Pharmacol. 48:209-214.
11. Iwamoto, M., L. A. Wenning, S. Y. Liou, J. T. Kost, E. Mangin, K. M. Strohmaier, T. C. Marbury, J. Stone, K. M. Gottesdiener, and J. A. Wagner. 2006. Rifampin (RIF) modestly reduces plasma levels of MK-0518, abstr. P299. 8th Int. Cong. Drug Ther. HIV Infect., Glasgow, Scotland, 12 to 16 November 2006.
12. Iwamoto, M., L. A. Wenning, A. S. Petry, M. Laethem, M. De Smet, J. T. Kost, S. A. Merschman, K. M. Strohmaier, S. Ramael, K. C. Lasseter, J. A. Stone, K. M. Gottesdiener, and J. A. Wagner. 2008. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 83:293-299.
13. Kassahun, K., I. McIntosh, D. Cui, D. Hreniuk, S. Merschman, K. Lasseter, N. Azrolan, M. Iwamoto, J. A. Wagner, and L. A. Wenning. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35:1657-1663.
14. Markowitz, M., J. O. Morales-Ramirez, B.-Y. Nguyen, C. M. Kovacs, R. T. Steigbigel, D. A. Cooper, R. Liporace, R. Schwartz, R. Isaacs, L. R. Gilde, L. A. Wenning, and J. Zhao. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515.
15. Markowitz, M., B. Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, C. Kovacs, G. Prada, J. O. Morales-Ramirez, C. S. Crumpacker, R. D. Isaacs, L. R. Gilde, H. Wan, M. D. Miller, L. A. Wenning, and H. Teppler. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection-results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
16. McCrea, J., D. Wyss, J. Stone, A. Carides, S. Kusma, C. Kleinbloesem, Y. AlHamdan, K. Yeh, and P. Deutsch. 1997. Pharmacokinetic interaction between indinavir and rifampin. Clin. Pharmacol. Ther. 61:I62.
17. Merck and Co., Inc. 2007. Isentress (raltegravir) 400 mg for treatment of HIV (NDA 22-145). FDA Antiviral Drugs Advisory Committee Meeting briefing document. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007 -4314b1-01-Merck.pdf.
18. Merschman, S. A., P. T. Vallano, L. A. Wenning, B. K. Matuszewski, and E. J. Woolf. 2007. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J. Chromatogr. B 857:15-24.
19. Miller, M. D., M. Witmer, K. Stillmock, P. Felcock, L. Ecto, J. Flynn, G. Dornadula, R. Danovich, and D. Hazuda. 2006. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor, abstr. THAA0302. AIDS 2006 - 16th Int. AIDS Conf., Toronto, Canada, 13 to 16 August 2006.
20. Steigbigel, R., P. Kumar, J. Eron, M. Markowitz, M. Loufty, J. Zhao, R. Isaacs, B.-Y. Nguyen, and H. Teppler. 2008. 48-Week results from BENCHMRK-2, a phase III study of raltegravir (RAL) in patients (pts) failing antiretroviral therapy (ART) with triple-class resistant HIV, abstr. J-117. 15th Conf. Retrovir. Opportun. Infect., Boston, MA, 3 to 6 February 2008.
21. Sugatani, J., S. Nishitani, K. Yamakawa, K. Yoshinari, T. Sueyoshi, M. Negishi, and M. Miwa. 2005. Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol. 67:845-855.
22. Wenning, L., B.-Y. Nguyen, X. Sun, E. Hwang, Y. Chen, H. Teppler, C. Harvey, R. Rhodes, D. Ryan, N. Azrolan, and J. Stone. 2008. Pharmacokinetic/ pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients, abstr. O21. 9th Int. Workshop Clin. Pharmacol. HIV Ther., New Orleans, LA, 7 to 9 April 2008.
23. Wenning, L. A., W. Hanley, J. Stone, A. Moreau, J. T. Kost, E. Mangin, T. Shamp, N. Azrolan, K. M. Gottesdiener, J. A. Wagner, and M. Iwamoto. 2006. Effect of tipranavir + ritonavir (tpv + rtv) on pharmacokinetics of MK-0518, abstr. A-374, p. 8. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 27 to 30 September 2006.